18 F-FDG PET and, more recently, PET/CT have been established as response biomarkers
for monitoring cytotoxic or cytoreductive cancer therapies. With the advent of targeted cancer …

PET with the glucose analog 18 F-FDG is increasingly being used to monitor the
effectiveness of therapy in patients with malignant lymphomas and a variety of solid tumors …

Sarcomas are a biologically complex group of diseases that exhibit variable responses to
single or combination therapy. 18 F-FDG PET imaging contributes to sarcoma treatment …

Purpose PET has been important for monitoring recurrence and metastasis of
Gastrointestinal Stromal Tumors (GISTs) and the selection of therapeutic strategies. A …

Gastrointestinal stromal tumors (GIST), rare mesenchymal tumors of the gastrointestinal
tract, are gaining the interest of researchers because of the impressive metabolic response …

Positron emission tomography (PET) is increasingly used to diagnose, grade, and stage
different types of tumors and to assess tumor response to therapy. Metabolic data acquired …

Functional imaging of solid tumors with positron emission tomography (PET) imaging is an
evolving field with continuous development of new PET tracers and discovery of new …

Despite the increasing use of 18F-FDG PET as a biomarker for predicting therapeutic
response, there are no widely accepted standardized protocols for using 18F-FDG PET as a …

Impact of 68Ga-FAPI-04 PET/CT on Staging and Therapeutic Man... : Clinical Nuclear Medicine
Impact of 68Ga-FAPI-04 PET/CT on Staging and Therapeutic Management in Patients With …

Positron emission tomography (PET) scanning with F18-fluoro-deoxyglucose or FDG is a
becoming a standard method for tumor staging. The prediction and evaluation of therapy …